1 / 6

Erdosteine Market Trends, Competitive And Regional Forecast To 2027

The erdosteine market is expected to witness substantial growth by 2027 owing to the rising incidences of chronic illnesses and rising focus on clinical development in the field.

marketreportsinsights
Download Presentation

Erdosteine Market Trends, Competitive And Regional Forecast To 2027

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Erdosteine Market Analytical Overview, Comprehensive Analysis, Segmentation, Competitive Landscape and Industry Poised for Rapid Growth 2027

  2. The erdosteine market is expected to witness substantial growth by 2027 owing to the rising incidences of chronic illnesses and rising focus on clinical development in the field. • Erdosteine is a commonly used mucoactive agent for treating several respiratory diseases. It is specifically used where the overlap of bacterial infection is more recurrent. The drug has also been approved for acute and chronic pulmonary diseases treatment. • It is a part of the thiol-based family of drugs, which possesses potentially significant anti-inflammatory and antioxidant properties. This class of drugs also demonstrates antibacterial activity against various medically prominent bacterial species. • Moreover, research has shown that erdosteine can prevent or reduce lung tissue damage resulting from oxidative stress. • The RESTORE study investigated the effects of a thiol-based drug in chronic obstructive pulmonary disease (COPD) frequent exacerbators. The study found that erdosteine could significantly lower the risk of acute exacerbations of COPD (AECOPDs). It also demonstrated that the drug shortened their course and reduced the need for hospitalization due to COPD.

  3. The study concluded that integrating erdosteine into the usual COPD maintenance therapy reduced the frequency of mild exacerbations and shortened the duration of all exacerbations in patients diagnosed with moderate COPD and a medical history of exacerbations. • After the COVID-19 outbreak, the pharmaceutical industry collectively focused their efforts on identifying treatment methods and finding a cure for the infection. • In October 2020, leading pharmaceutical firm Recipharm announced that it had successfully concluded the research study exploring the use of erdosteine as an add-on when treating COVID-19 infected patients. The company stated that its proprietary molecule had tested positive as part of the COVID-19 treatment. • Browse key industry insights spread across 130 pages with 63 market data tables and 39 figures & charts from the report, “Erdosteine Market” in detail along with the table of contents @ https://www.gminsights.com/industry-analysis/erdosteine-market

  4. Request for a Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/3371

  5. Latest Research Report On Erdosteine Market @ https://www.gminsights.com/industry-analysis/erdosteine-market Request for a Sample Copy of this Report @ https://www.gminsights.com/request-sample/detail/3371 Request for customization @ https://www.gminsights.com/roc/3371

  6. THANK YOU www.gminsights.com

More Related